The first generic version of Exelon (rivastigmine tartrate), a popular drug for treating mild to moderate dementia, appeared on the U.S. market this week, giving providers and seniors a more economical alternative to the branded drug. Rivastigmine is used to treat the cognitive issues associated with Alzheimer’s disease and Parkinson’s disease.
Swiss drug manufacturer Acino launched the drug in a transdermal patch form and in three doseage strengths. It is being sold in the United States by Acino’s licensing partner, Alvogen.
The generic rivastigmine patch has been used in the UK and parts of Europe for several years.